
Maze Therapeutics, Inc.
100
Recent developments for Maze Therapeutics include reporting wider losses in Q2 2026, positive Phase 2 data for MZE829, insider share sales, and analyst coverage with buy recommendations. The company also completed a significant stock offering and anticipates Phase 2 data for MZE782 in fiscal year 2027.
- Maze Therapeutics reported a wider loss in Q2 2026 and announced expectations for Phase 2 CIPheR data for MZE782 in fiscal year 2027 [N4].
- The company reported positive Phase 2 data for its kidney disease drug candidate MZE829 in March 2026 [N6].
- Maze Therapeutics' Chief Medical Officer sold his entire direct stake in the company for $255,000 in September 2026 [N3].
- The company completed a $150 million stock and pre-funded warrants offering in April 2026 [N7].
- Analyst coverage was initiated with buy and outperform recommendations from Truist Securities and Mizuho in early 2026 [N6].
- Wall Street analysts have publicly discussed upside potential for Maze Therapeutics, citing upside percentages near 93.92% and 123.39% in late 2026 [N1][N2].
Maze Therapeutics, Inc. operates as a clinical-stage biotechnology company developing novel therapeutics. The company focuses on advancing drug candidates through clinical trials, including MZE829 for kidney disease and MZE782, with Phase 2 clinical data anticipated for MZE782 in fiscal year 2027. Maze Therapeutics maintains a strong liquidity position with substantial cash and short-term investments relative to its liabilities. The company has engaged in equity offerings to support its development programs and has experienced insider stock sales. Analyst coverage has been initiated with buy and outperform ratings, reflecting interest in the company's clinical progress and pipeline potential.
Maze Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics, with recent positive Phase 2 data for its kidney disease drug candidate MZE829 and ongoing development of MZE782. The company reported a net loss of $47.969 million for Q3 2026 and maintains strong liquidity with over $389 million in cash and short-term investments as of September 30, 2026. Insider share sales have occurred recently, and the company has attracted analyst coverage with positive recommendations. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The bull case for Maze Therapeutics centers on its positive Phase 2 clinical data for MZE829 and the upcoming Phase 2 data for MZE782, which could validate its therapeutic approach. Strong liquidity supports ongoing development activities. Analyst coverage with buy and outperform recommendations indicates market interest and confidence in the company's pipeline. Successful clinical milestones could enhance the company's value proposition and attract further investment.
The bear case involves the risks typical of clinical-stage biotechnology companies, including the possibility of clinical trial failures, regulatory hurdles, and the need for additional financing. Recent insider sales may raise concerns about management's confidence. The company reported a net loss and negative earnings per share, reflecting ongoing expenses without revenue generation. Market and competitive pressures in the biotech sector could also impact the company's prospects.
Maze Therapeutics' moat is primarily based on its proprietary therapeutic candidates in clinical development and its platform for identifying novel drug targets. The company's focus on genetically validated targets and clinical-stage assets provides a specialized niche in biotechnology. However, as a clinical-stage company without approved products, its competitive advantage depends on successful clinical development and regulatory approvals, which remain uncertain and subject to risks inherent in drug development.
• Clinical Development Risk: Maze Therapeutics faces the inherent risk that its drug candidates may not demonstrate safety or efficacy in clinical trials, which could delay or prevent regulatory approval.
• Financial Risk: The company currently operates at a net loss and depends on its cash reserves and potential future financing to fund operations, which may be insufficient if development timelines extend.
• Regulatory Risk: Obtaining regulatory approval for novel therapeutics involves complex and uncertain processes that could impact the company's ability to commercialize its products.
• Insider Selling: Recent insider sales of shares by executives may be perceived negatively by investors and could impact market sentiment.
Business trends: The company is advancing clinical development of therapeutic candidates MZE829 and MZE782, with reported positive Phase 2 data for MZE829 and anticipated Phase 2 data for MZE782. Execution milestones: Completion and reporting of Phase 2 clinical trials for MZE782; maintaining strong liquidity and managing insider share transactions. Key risks: Clinical trial outcomes, regulatory approval challenges, financial sustainability given ongoing losses, and market perception influenced by insider stock sales.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Maze Therapeutics, Inc. is a publicly traded company on Nasdaq under the ticker MAZE [S1].
- As of November 4, 2026, Maze Therapeutics had 54,683,345 shares of common stock outstanding [S1].
- The company is incorporated in Delaware and headquartered in South San Francisco, California [S1].
- Maze Therapeutics reported a net loss of $47.969 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.79 per share [S2].
- As of September 30, 2026, Maze Therapeutics held $154.156 million in cash and equivalents and $235.502 million in short-term investments, totaling $389.658 million in liquid assets [S2].
- The company had current assets of $400.102 million and current liabilities of $28.3 million as of September 30, 2026, resulting in a current ratio of 14.14 and a cash ratio of 13.77, indicating strong liquidity [S2].
- Maze Therapeutics is engaged in clinical development of therapeutic candidates, including MZE829 for kidney disease and MZE782, with Phase 2 clinical data expected for MZE782 in fiscal year 2027 [N4].
- The company reported positive Phase 2 data for MZE829 in March 2026 [N6][N4].
- Maze Therapeutics has experienced insider sales, including the Chief Medical Officer selling his entire direct stake for $255,000 in September 2026 and prior sales of shares by other executives [N3][N8].
- The company has received analyst coverage with buy and outperform recommendations from firms such as Truist Securities and Mizuho in early 2026 [N6].
- Maze Therapeutics has conducted stock offerings, including a $150 million stock and pre-funded warrants offering in April 2026 [N7].
- Recent news articles discuss significant upside potential as perceived by Wall Street analysts, with upside percentages cited around 93.92% and 123.39% in late 2026 [N1][N2].
Generated 2026-11-11
- S1 | 2026-03-25 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-04 | www.nasdaq.com | Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know | https://www.nasdaq.com/articles/wall-street-analysts-predict-9392-upside-maze-therapeutics-inc-maze-heres-what-you-should
- N2 | 2026-10-19 | www.nasdaq.com | How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% | https://www.nasdaq.com/articles/how-much-upside-left-maze-therapeutics-inc-maze-wall-street-analysts-think-12339
- N3 | 2026-09-11 | www.nasdaq.com | Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 | https://www.nasdaq.com/articles/maze-therapeutics-chief-medical-officer-dumps-entire-direct-stake-company-255000
- N4 | 2026-08-12 | www.nasdaq.com | Maze Posts Wider Loss In Q2; Expects Phase 2 CIPheR Data For MZE782 In FY27 | https://www.nasdaq.com/articles/maze-posts-wider-loss-q2-expects-phase-2-cipher-data-mze782-fy27
- N5 | 2026-07-21 | www.nasdaq.com | Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? | https://www.nasdaq.com/articles/can-maze-therapeutics-inc-maze-climb-12048-reach-level-wall-street-analysts-expect
- N6 | 2026-05-12 | www.nasdaq.com | Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/maze-therapeutics-inc-maze-reports-q1-loss-beats-revenue-estimates
- N7 | 2026-05-07 | www.nasdaq.com | Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials | https://www.nasdaq.com/articles/maze-therapeutics-csbo-sells-7500-shares-190000-after-strong-trial-results-and-q4
- N8 | 2026-04-04 | www.nasdaq.com | Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. | https://www.nasdaq.com/articles/maze-therapeutics-chief-medical-officer-sold-100-his-direct-holdings-heres-what-means
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


